3 Stocks Pulling The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.
By TheStreet Wire ,

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 137 points (0.7%) at 18,509 as of Thursday, July 14, 2016, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,870 issues advancing vs. 1,053 declining with 127 unchanged.

The Health Care sector currently sits down 0.2% versus the S&P 500, which is up 0.5%. A company within the sector that fell today was

HCA Holdings

(

HCA

), up 1.4%. Top gainers within the sector include

Valeant Pharmaceuticals International

(

VRX

), up 3.4%,

Biomarin Pharmaceutical

(

BMRN

), up 1.9%,

Alibaba Group

(

BABA

), up 1.7%,

Amgen

(

AMGN

), up 1.3% and

Alexion Pharmaceuticals

(

ALXN

), up 1.1%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3.

Acadia Healthcare

(

ACHC

) is one of the companies pushing the Health Care sector lower today. As of noon trading, Acadia Healthcare is down $2.80 (-5.0%) to $53.62 on heavy volume. Thus far, 2.8 million shares of Acadia Healthcare exchanged hands as compared to its average daily volume of 736,000 shares. The stock has ranged in price between $50.91-$57.28 after having opened the day at $56.47 as compared to the previous trading day's close of $56.43.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Acadia Healthcare Company, Inc. Acadia Healthcare has a market cap of $4.9 billion and is part of the health services industry. Shares are down 9.7% year-to-date as of the close of trading on Wednesday. Currently there are 11 analysts that rate Acadia Healthcare a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates

Acadia Healthcare

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations, impressive record of earnings per share growth and compelling growth in net income. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

Acadia Healthcare Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Regeneron Pharmaceuticals

(

REGN

) is down $2.45 (-0.7%) to $362.05 on light volume. Thus far, 164,224 shares of Regeneron Pharmaceuticals exchanged hands as compared to its average daily volume of 907,600 shares. The stock has ranged in price between $360.98-$367.02 after having opened the day at $366.47 as compared to the previous trading day's close of $364.50.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. Regeneron Pharmaceuticals has a market cap of $38.7 billion and is part of the drugs industry. Shares are down 32.9% year-to-date as of the close of trading on Wednesday. Currently there are 8 analysts that rate Regeneron Pharmaceuticals a buy, 2 analysts rate it a sell, and 10 rate it a hold.

TheStreet Ratings rates

Regeneron Pharmaceuticals

as a

hold

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and impressive record of earnings per share growth. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and poor profit margins. Get the full

Regeneron Pharmaceuticals Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

AbbVie

(

ABBV

) is down $1.26 (-1.9%) to $63.51 on average volume. Thus far, 6.2 million shares of AbbVie exchanged hands as compared to its average daily volume of 9.1 million shares. The stock has ranged in price between $62.94-$64.14 after having opened the day at $63.70 as compared to the previous trading day's close of $64.77.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. AbbVie has a market cap of $105.9 billion and is part of the drugs industry. Shares are up 9.3% year-to-date as of the close of trading on Wednesday. Currently there are 7 analysts that rate AbbVie a buy, 1 analyst rates it a sell, and 6 rate it a hold.

TheStreet Ratings rates

AbbVie

as a

buy

. The company's strengths can be seen in multiple areas, such as its impressive record of earnings per share growth, compelling growth in net income, robust revenue growth, good cash flow from operations and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full

AbbVie Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care

(

RXD

).

Loading ...